Both Surgery, Definitive Concurrent CRT Acceptable for Resectable NSCLC

Both surgery and definitive concurrent chemoradiotherapy boost are acceptable treatment strategies for non-small cell lung cancer.
Both surgery and definitive concurrent chemoradiotherapy boost are acceptable treatment strategies for non-small cell lung cancer.

Both surgery and definitive concurrent chemoradiotherapy boost are acceptable treatment strategies for patients with resectable stage 3A(N2) and selected stage 3B non-small cell lung cancer (NSCLC) after induction chemotherapy and concurrent chemoradiotherapy, a new study published online ahead of print in the Journal of Clinical Oncology has shown.1

A previous phase 2 study demonstrated that induction chemotherapy followed by chemoradiotherapy and surgery is efficacious in patients with stage 3A(N2) disease and certain patients with stage 3B NSCLC.

For the phase 3 study, researchers enrolled 246 patients with pathologically proven 3A(N2) and selected patients with 3B disease that were eligible for further treatment after receiving induction chemotherapy consisting of cisplatin and paclitaxel, as well as concurrent chemoradiotherapy with cisplatin and vinorelbine.

After induction, 161 patients with resectable tumors were randomly assigned to receive a chemoradiotherapy boost or to undergo surgery.

Results showed no significant difference in 5-year overall survival or 5-year progression-free survival between the 2 treatment arms.

Overall survival rates were 44% in the surgery arm and 40% in the chemoradiotherapy boost arm, and progression-free survival rates were 32% and 35%, respectively. Of the 246 patients enrolled, 34.1% were still alive at 5 years.

“The 5-year OS and PFS rates in randomly assigned patients with resectable stage III non-small cell lung cancer were excellent with both treatments,” the authors conclude.

REFERENCE

1. Eberhardt WEE, Pöttgen C, Gauler TC, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy [published online ahead of print November 2, 2015]. J Clin Oncol. doi:10.1200/JCO.2015.62.6812.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs